Blog Reports
Check DailyStock reports by date and topic.
-
![[Nasdaq Story] The 'Dangerous Divergence' Between the SOX Semiconductor Index and Nasdaq: The AI Bubble Debate and 4.5% Treasury Yield Shock Left by a 10.26% Plunge](https://daily-stock.kr/stdaily/uploads/202606/gen_6a23636a60c819.50145928.png)
[Nasdaq Story] The 'Dangerous Divergence' Between the SOX Semiconductor Index and Nasdaq: The AI Bubble Debate and 4.5% Treasury Yield Shock Left by a 10.26% Plunge
The hottest topic in the US stock market is the unprecedented decoupling between the Philadelphia Semiconductor Index (SOX) and the Nasdaq Composite, followed by a shocking downturn, sparked by a 10.26% single-day plunge in the SOX index.
-
KOSDAQ Anchors at 1,002 Level; Examining Classys' (214150) 15% US Revenue Target and Global Expansion Strategy
Global medical aesthetics leader Classys (214150) is accelerating its expansion in the US, the world's largest aesthetic medical market, presenting a long-term roadmap with a 15% revenue share target for North America.
-
![[KOSPI Story] SK Hynix (000660) Plummets 9.92% Amid 'Broadcom Shock'; A Check on HBM Shipment Roadmap](https://daily-stock.kr/stdaily/uploads/202606/gen_6a2274476ca7c2.56098786.png)
[KOSPI Story] SK Hynix (000660) Plummets 9.92% Amid 'Broadcom Shock'; A Check on HBM Shipment Roadmap
Amid a sharp market correction on June 5, 2026, sparked by disappointing tech guidance and foreign outflows, SK Hynix fell 9.92%. However, its HBM4 and next-generation HBM4E shipment roadmaps remain firmly on track.
-
GDPNow Adjusted to 3.0% and Mixed Economic Indicators: Diagnosing the S&P 500's Soft Landing Path
Recent adjustments to the GDPNow estimate, a key indicator of real-time U.S. economic growth, are drawing close attention from financial markets. Real PCE and GPDI forecasts have been revised downward.
-
US PCE Exceeds 3.3% and Nasdaq Multiples: Assessing Big Tech's Earnings Resilience Amid 4.6% Treasury Yield Pressure
Daily Stock analyzes the impact of the US 4.1% core PCE rise to 3.3% and the 10-year Treasury yield hitting 4.67% on Nasdaq multiples, highlighting how Big Tech earnings growth supports market valuation.
-
KOSDAQ at 1,049: Exploring Clinical Trial Calendars Driven by ADA & Clinical Momentum alongside Valuations of Top 3 Leaders (Alteogen, ABL Bio, Peptron)
KOSDAQ looks to regain momentum with upcoming major conferences like ADA 2026. This article analyzes the technology, clinical calendars, and valuations of top biotech platforms Alteogen, ABL Bio, and Peptron.